A randomised, single centre, phase IV crossover study to assess the acceptability of once daily Zindaclin® used for one week compared to three other marketed topical antibiotics in patients with mild to moderate acne

Completed

• Conditions: Mild to moderate acne vulgaris.; Skin and Connective Tissue Diseases; Acne

• Registration Number: ISRCTN43187439
• Lead Sponsor: ProStrakan Pharmaceuticals (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10-06
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

Male and female patients aged between 16 and 40 years with mild to moderate acne graded between 1.0 and 7.0 on the Leeds Revised Acne Grading System, 1998.

Exclusion Criteria

1. Patients with acne conglobata, acne fulminans, sandpaper acne, submarine comedonal acne or secondary acne were excluded
2. The use of topical or systemic antibiotics or topical antimicrobials within the previous week was disallowed

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient Acceptability Questionnaire assessing the four study products.

Secondary Outcome Measures

Name	Time	Method
1. A conjoint analysis assessment of product preferences<br>2. The level of product use